Evaluation of pharmacological therapies for Friedreich ataxia using cellular and mouse models [ 2008 - 2010 ]

Research Grant

Researchers: Prof Martin Delatycki (Principal investigator) ,  Dr Joseph Sarsero ,  Mark Pook

Brief description Friedreich ataxia (FRDA) is an inherited disorder of the nervous system and muscles. The genetic defect that causes FRDA results in reduced levels of an essential protein termed frataxin. By using information and resources generated as part of the Human Genome Project we have developed new techniques to study human gene expression in cellular and animal systems. Our aim is to identify and develop new pharmacological approaches for the restoration of FRDA gene expression and the therapy of FRDA.

Funding Amount $AUD 589,425.35

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant